M&R Capital Management’s Pacira BioSciences PCRX Stock Holding History

M&R Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-700	Closed	-$23.6K	–	612
2023 Q4	$23.6K	Hold	700	–	–	0.01%	311
2023 Q3	$21.5K	Hold	700	–	–	0.01%	307
2023 Q2	$28K	Buy	+700	New	+$28.9K	0.01%	294

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

M&R Capital Management's PCRX Position: Q1 2024 in Review

M&R Capital Management sold out of Pacira BioSciences (PCRX) in Q1 2024, closing a stake of 700 shares — an estimated $23.6K sold.

M&R Capital Management first reported a position in PCRX in Q2 2023 and held it in 3 quarters. The position peaked at $28K in Q2 2023. 270 funds tracked by Wall St. Rank hold PCRX as of Q1 2024.

M&R Capital Management reported no remaining Pacira BioSciences position as of Q1 2024 after selling out during the quarter.
M&R Capital Management sold 700 Pacira BioSciences shares in Q1 2024, an estimated $23.6K.
M&R Capital Management first reported a position in Pacira BioSciences in Q2 2023 and held it in 3 quarters.
M&R Capital Management's Pacira BioSciences position peaked at $28K in Q2 2023.
270 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2024.

Based on M&R Capital Management's 13F filing for Q1 2024, filed 2 Apr 2024.